Screening for and prevention of the progression of microalbuminuria in diabetes mellitus. (ACE-I stands for angiotensin-converting enzyme inhibitor)

( more information: http://care.diabetesjournals.org/con...ppl_1/s79.full )

(???) Avosentan May Reduce Proteinuria but Serious Adverse Effects Occur in Patients With Type 2 Diabetes, Kidney Disease? 

--> Avosentan Not a Viable Therapeutic Option
"Avosentan reduces albuminuria when added to standard treatment in people with type 2 diabetes and overt nephropathy but induces significant fluid overload and congestive heart failure," the study authors write. "Of particular concern was a trend to a higher mortality with avosentan."
(http://www.medscape.com/viewarticle/717239)

(???) Dual Inhibition With Losartan and Aliskiren: A Promising Therapeutic Option for Type 2 Diabetic Nephropathy?
-->the recently published AVOID (Aliskiren in the Evaluation of Proteinuria in Diabetes) trial, dual blockade of the renin-angiotensin-aldosterone system reduced albuminuria